Home Newsfeeds Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

byBenzinga Newsdesk

October 13, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

Tennessee Rep. Mark Dr Green Sold Over $50K Worth of Energy Transfer Stock: Here’s What You Should Know

By Benzinga Insights

February 28, 11:05 AM

Representative Mark Dr Green from Tennessee reported a sale of Energy Transfer (NYSE:ET) stock, according to a February…

EXCLUSIVE: MariMed CEO Discusses Evolving Illinois Cannabis Market, Rescheduling

By Nicolas Jose Rodriguez

September 28, 9:23 AM

Jon Levine, CEO of multi-state cannabis operator, MariMed (OTC: MRMD), and Erik Sloane, Global Head of Corporate Listings at Cboe Canada, discussed the evolving Illinois cannabis market at the

MRMD

Analyst Ratings

Expert Outlook: ACM Research Through The Eyes Of 4 Analysts

By Benzinga Insights

January 11, 5:00 PM

Throughout the last three months, 4 analysts have evaluated ACM Research (NASDAQ:ACMR), offering a diverse set of opinions…

ACMR

Jim Cramer Calls Major Automaker Stock A ‘Wait And See Situation’ — ‘I Want To See The Quarter’

By Lisa Levin

November 22, 10:18 AM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Grab Holdings Limited (NASDAQ: GRAB) is losing too much money.

ASO

Oppenheimer Downgrades Relmada Therapeutics to Perform

Related Posts

Tennessee Rep. Mark Dr Green Sold Over $50K Worth of Energy Transfer Stock: Here’s What You Should Know

EXCLUSIVE: MariMed CEO Discusses Evolving Illinois Cannabis Market, Rescheduling

Expert Outlook: ACM Research Through The Eyes Of 4 Analysts

Jim Cramer Calls Major Automaker Stock A ‘Wait And See Situation’ — ‘I Want To See The Quarter’